Journal of Clinical Oncology, Vol 9, 1675-1681, Copyright © 1991 by American Society of Clinical Oncology

ARTICLES

Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin, and fluorouracil

H Boussen, E Cvitkovic, JL Wendling, N Azli, M Bachouchi, R Mahjoubi, C Kalifa, P Wibault, G Schwaab and JP Armand
Institut Gustave Roussy, Villejuif, France.

Undifferentiated nasopharyngeal carcinoma (UCNT) is known to be radiosensitive and chemosensitive, but the latter has never been studied prospectively with phase II methodology. After an intensive work-up, 49 patients with recurrent (REC) and/or metastatic (MTS) UCNT were treated with three monthly cycles of cisplatin (CDDP) 100 mg/m2 day 1; bleomycin 15 mg intravenously (IV) day 1, and 16 mg/m2/d continuous infusion (CI) days 1 to 5; and fluorouracil (5FU) 650 mg/m2/d CI days 1 to 5 (PBF). Of the 49 patients, 33 were North African. The sex ratio was three males:one female, and the median World Health Organization (WHO) performance status was 1.6. In the 48 patients assessable for response, we observed nine (19%) complete responses (CRs) and 29 (60%) partial responses (PRs) (60%), for a 79% overall response rate (95% confidence interval, 68% to 90%) in the assessable group and a 78% global rate. There were eight CRs (24%) observed in the group without previous chemotherapy (33 patients) compared with one CR in the chemotherapy pretreated group (16 patients). Four patients are still alive without evidence of disease after 52+, 54+, 58+, and 58+ months, respectively. All of them had less than three bone MTS sites, and received radiation therapy in these sites. The results confirm the chemosensitivity of UCNT, and the observation of unmaintained long-term responders makes curability a possible consideration.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. Zhang, C. Zhao, P.-J. Peng, L.-X. Lu, P.-Y. Huang, F. Han, and S.-X. Wu Phase III Study Comparing Standard Radiotherapy With or Without Weekly Oxaliplatin in Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Preliminary Results J. Clin. Oncol., November 20, 2005; 23(33): 8461 - 8468. [Abstract] [Full Text] [PDF]

				T.-Y. Chen, H. H. W. Chen, W.-C. Su, and C.-J. Tsao High-dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Patients with Nasopharyngeal Cancer: a Feasibility Study Jpn. J. Clin. Oncol., July 1, 2003; 33(7): 331 - 335. [Abstract] [Full Text] [PDF]

				J.-C. Lin, J.-S. Jan, C.-Y. Hsu, W.-M. Liang, R.-S. Jiang, and W.-Y. Wang Phase III Study of Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Advanced Nasopharyngeal Carcinoma: Positive Effect on Overall and Progression-Free Survival J. Clin. Oncol., February 15, 2003; 21(4): 631 - 637. [Abstract] [Full Text] [PDF]

				R. K. C. Ngan, H. H. Y. Yiu, W. H. Lau, S. Yau, F. Y. Cheung, T. M. Chan, C. H. Kwok, C. Y. Chiu, S. K. Au, W. Foo, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study Ann. Onc., August 1, 2002; 13(8): 1252 - 1258. [Abstract] [Full Text] [PDF]

				A. T. C. Chan, P. M. L. Teo, and P. J. Johnson Nasopharyngeal carcinoma Ann. Onc., July 1, 2002; 13(7): 1007 - 1015. [Abstract] [Full Text] [PDF]

				D. Rischin and L. J. Peters The Local-Regionally Advanced Nasopharyngeal Carcinoma Jigsaw Puzzle: Where Does the Chemotherapy Piece Fit? J. Clin. Oncol., April 15, 2002; 20(8): 1968 - 1970. [Full Text] [PDF]

				D. Rischin, J. Corry, J. Smith, J. Stewart, P. Hughes, and L. Peters Excellent Disease Control and Survival in Patients With Advanced Nasopharyngeal Cancer Treated With Chemoradiation J. Clin. Oncol., April 1, 2002; 20(7): 1845 - 1852. [Abstract] [Full Text] [PDF]

				K.-F. Foo, E.-H. Tan, S.-S. Leong, J. T. S. Wee, T. Tan, K.-W. Fong, L. Koh, B.-C. Tai, L.-G. Lian, and D. Machin Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type Ann. Onc., January 19, 2002; 13(1): 150 - 156. [Abstract] [Full Text] [PDF]

				N. Fuwa, Y. Ito, T. Kodaira, A. Matsumoto, M. Kamata, K. Furutani, H. Tatibana, M. Sasaoka, and K. Morita Therapeutic Results of Alternating Chemoradiotherapy for Nasopharyngeal Cancer using Cisplatin and 5-Fluorouracil: Its Usefulness and Controversial Points Jpn. J. Clin. Oncol., December 1, 2001; 31(12): 589 - 595. [Abstract] [Full Text] [PDF]

				J. Ma, H.-Q. Mai, M.-H. Hong, H.-Q. Min, Z.-D. Mao, N.-J. Cui, T.-X. Lu, and H.-Y. Mo Results of a Prospective Randomized Trial Comparing Neoadjuvant Chemotherapy Plus Radiotherapy With Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma J. Clin. Oncol., March 1, 2001; 19(5): 1350 - 1357. [Abstract] [Full Text] [PDF]

				A. Fandi, M. Bachouchi, N. Azli, A. Taamma, H. Boussen, P. Wibault, F. Eschwege, J.-P. Armand, J. Simon, and E. Cvitkovic Long-Term Disease-Free Survivors in Metastatic Undifferentiated Carcinoma of Nasopharyngeal Type J. Clin. Oncol., March 13, 2000; 18(6): 1324 - 1330. [Abstract] [Full Text] [PDF]